{"schema_version":"secwatch.filing_event.v1","accession":"0000059478-26-000077","form_type":"8-K","ticker":"LLY","cik":"0000059478","company_name":"ELI LILLY & Co","filed_at":"2026-08-05T11:05:09+00:00","discovered_at":"2026-08-05T11:10:00.421066+00:00","generated_at":"2026-08-05T11:10:52.264801+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Lilly Q2 revenue up 48% to $23.0B; raises full-year guidance","bullets":["Q2 2026 revenue $22,974M (+48% YoY); reported EPS $7.94 (+26%), non-GAAP EPS $8.38 (+33%).","Full-year revenue guidance raised to $85.0-87.0B; non-GAAP EPS guidance $35.50-$36.50 (up $2.78 midpoint).","Q2 EPS includes $3.03/share of acquired IPR&D charges from business development activity.","Completed acquisitions of Orna, Ajax, Centessa, Kelonia; post-quarter added infectious disease assets and AtaiBeckley.","Committed $4.5B to expand Indiana manufacturing sites; retatrutide Phase 3 data complete for global registrations."],"urls":{"canonical":"https://secwatch.observer/filing/0000059478-26-000077","json":"https://secwatch.observer/filing/0000059478-26-000077.json","markdown":"https://secwatch.observer/filing/0000059478-26-000077.md","text":"https://secwatch.observer/filing/0000059478-26-000077.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/59478/000005947826000077/0000059478-26-000077-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/59478/000005947826000077/lly-20260805.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-05T11:10:52.264801+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}